

the deviance used for inclusion in and exclusion from the model.

**Results** 229 SLE patients were included, and baseline characteristics are summarised in table 1. Total follow-up 3448 patient-years; median (IQR) follow up time was 11.6 (6.7, 21.4) years. Intensive therapy was initiated in 110 (48%) patients. The median (IQR) time to intensive therapy was 2 (0.5,8) years. Rituximab was the most common intensive therapy followed by cyclophosphamide (51.8% and 40.9%, respectively). In UVA, factors associated with increased risk of intensive therapies requirement were antibodies positivity for anti-Ro, anti-Sm and anti-RNP, cumulative number of Ab positivity, low complement levels, 2019 EULAR/ACR criteria score  $\geq 20$ , and higher cSLEDAI-2K score. While in MVA, anti-Ro+, low complement levels, and higher cSLEDAI-2K were associated with increased risk of intensive therapies requirement.

**Conclusions** Nearly half of SLE patients required intensive therapy and this was predicted by anti-Ro+, low complement levels, and high clinical-SLEDAI-2K score at SLE diagnosis. At present, it is unclear whether patients should receive initial antimalarials, then immunosuppressants, then biologic therapies, or whether some patients should receive a first-line biologic therapy. Our data suggest that patients with these predictive factors develop more severe SLE, fail conventional therapies, and therefore are suitable for first-line biologic therapy. If our results can be validated, then such a strategy may prevent severe SLE.

#### P156 RECOMMENDATIONS OF NONPHARMACOLOGICAL MANAGEMENT OF SLE AND SSC: ASSESSING ALIGNMENT WITH CLINICAL CARE

<sup>1,2</sup>Francesca Marchiori, <sup>3,4</sup>Rita Schriemer, <sup>4</sup>Els van den Ende, <sup>5</sup>Agnes Kocher, <sup>6</sup>Valentin Ritschl, <sup>2</sup>Birgit Barten, <sup>7</sup>Ilaria Galetti, <sup>8</sup>Rene Westhovens, <sup>9</sup>Oliver Distler, <sup>10</sup>Carina Bostrom, <sup>10</sup>Ioannis Parodis. <sup>1</sup>Lupus Europe, Brussels, Belgium; <sup>2</sup>EULAR-PARE, Kilchberg, Switzerland; <sup>3</sup>NVLE, Nijmegen, The Netherlands; <sup>4</sup>Sint Maartenskliniek, Nijmegen, The Netherlands; <sup>5</sup>Universität Basel, Basel, Switzerland; <sup>6</sup>Medical University of Vienna, Vienna, Austria; <sup>7</sup>FESCA, Saint-Maur, Belgium; <sup>8</sup>Universiteit Leuven, Leuven, Belgium; <sup>9</sup>University of Zurich, Zurich, Switzerland; <sup>10</sup>Karoliska Institutet, Stockholm, Sweden

10.1136/lupus-2024-el.210

**Background** Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) have a high disease burden which cannot be sufficiently alleviated with pharmacological treatment alone. In summer 2023 EULAR recommendations for non-pharmacological management of SLE and SSc were published <https://doi.org/10.1136/ard-2023-224416>.

Dissemination and implementation of the recommendations into daily clinical practice is crucial due to the impact on patients QoL and on a holistic management of these diseases. **Methods** We first aim at raising awareness of the recommendations to ensure adoption in clinical practice.

Twelve European national teams consisting of patient representatives, Health professionals (HPRs), and physicians engaging in the care of people with SLE and SSc have been formed.

Each national team will disseminate the recommendations, e.g., in the form of translations, publications, mailings, presentations (step 1).

An online survey (step 2) will be prepared, translated, checked by native speakers, and pilot-tested in a smaller group of patients. The survey gauges both the professional and

experiential opinion of stakeholders' perceived alignment of each recommendation with current clinical practice in their respective countries. The survey will be circulated to SLE and SSc patients, HPRs, and physicians. Qualitative data will be translated, checked by native speakers, and analysed using qualitative methodology. Project reports results including the result of the analysis will be published both at national, and global level (step 3).

The role of patient representative is key in all the steps.

**Results** The first twelve national teams were formed in Switzerland, Austria, Belgium, Germany, Greece, Hungary, Italy, Portugal, Sweden, United Kingdom, Denmark, the Netherlands. The congress is the occasion for discussing the EULAR recommendations, showing the first results of the national teams disseminating the recommendations and inviting stakeholders from other countries to participate in the project and in its next steps.

**Conclusions** This project aims to provide a foundation for disseminating and implementing the recent published EULAR recommendations for the non-pharmacological management of SLE and SSc. All stakeholder groups involved can use their network to disseminate the recommendations and amplify the reach of the recommendations in a multi-tiered approach. In this action research, the role of patient representatives is key.


#### P157 BARICITINIB FOR THE TREATMENT OF RHUPUS SYNDROME

Pablo Martínez Calabuig, Jorge Juan Fragío Gil, Roxana González Mazarío, Sara Moner Marín, Laura Salvador Maicas, Mireia Sanmartín Martínez, Amalia Rueda Cid, Juan José Lerma Garrido, Clara Molina Almela, Cristina Campos Fernández. *Dept. of Rheumatology, Consortium Hospital General University, Valencia, Spain*

10.1136/lupus-2024-el.211

**Objectives** To assess the effectiveness and safety of baricitinib in the treatment of Rhupus.

**Methods** We conducted a retrospective observational review of medical records from the Rheumatology Department at our hospital between 2019 and 2023, identifying patients diagnosed with Rhupus, who received baricitinib. The diagnosis of Rhupus was assigned to patients who met the diagnostic criteria for both Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). The study involves a comprehensive analysis of clinical outcomes and medication safety profiles for these patients.



**Abstract P157 Figure 1** Comparative analysis of Rhupus activity parameters over time in patients treated with baricitinib